Rates for Anaphylaxis for Patients with Rheumatoid Arthritis Treated with Tocilizumab or Other Biologics: An Analysis Based on Health Claims Data

02/05/2017
30/03/2024
EU PAS number:
EUPAS18844
Study
Finalised
Study identification

EU PAS number

EUPAS18844

Study ID

18901

Official title and acronym

Rates for Anaphylaxis for Patients with Rheumatoid Arthritis Treated with Tocilizumab or Other Biologics: An Analysis Based on Health Claims Data

DARWIN EU® study

No

Study countries

United States

Study description

No information provided.

Study status

Finalised
Research institutions and networks

Institutions

Contact details

Khaled Sarsour

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Data analysis start date

Actual:

Date of final study report

Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

F. Hoffmann-La Roche Ltd
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)